 |
||||
| 2007 JASN IMPACT FACTOR 7.111 | HOME AUTHOR INFO EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP | |||
| CURRENT ISSUE | ARCHIVES | JASN Express | ONLINE SUBMISSION | |
|
||||
| 2007 JASN IMPACT FACTOR 7.111 | HOME AUTHOR INFO EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP | |||
| CURRENT ISSUE | ARCHIVES | JASN Express | ONLINE SUBMISSION | |
Hyonam Kidney Laboratory, Soon Chun Hyang University, Seoul, Korea.
Correspondence to Dr. Hi Bahl Lee, Hyonam Kidney Laboratory, Soon Chun Hyang University, 657 Hannam Dong, Yongsan Ku, Seoul 140-743, Korea. Phone: +82 2 709 9171, +82 2 792 6657; Fax: +82 2 792 5812; E-mail: hblee{at}korea.com
Abstract. Diabetic nephropathy is a leading cause of end-stage renal disease and is characterized by excessive deposition of extracellular matrix (ECM) proteins in the glomeruli. Transforming growth factor-ß (TGF-ß) is the major mediator of excessive accumulation of ECM proteins in diabetic nephropathy through upregulation of genes encoding ECM proteins as well as downregulation of genes for ECM-degrading enzymes. It has been shown that lovastatin, an inhibitor of 3-hydroxy-3-methylglutaryl CoA reductase, delays the onset and progression of different models of experimental nephropathy. To evaluate the effect of lovastatin on the development and progression of diabetic nephropathy, streptozotocin-induced diabetic rats were studied for 12 mo. In untreated diabetic rats, there were significant increases in blood glucose, urine albumin excretion, kidney weight, glomerular volume, and TGF-ß1 mRNA expression in the glomeruli compared with normal control rats treated with citrate buffer only. Treatment with lovastatin in diabetic rats significantly suppressed the increase in urine albumin excretion, kidney weight, glomerular volume, and TGF-ß1 mRNA expression despite high blood glucose levels. To elucidate the mechanisms of the renal effects of lovastatin, rat mesangial cells were cultured under control (5.5 mM) or high (30 mM) glucose with lovastatin alone, mevalonate alone, or with both. Under high glucose, TGF-ß1 and fibronectin mRNA and proteins were upregulated. These high glucose-induced changes were suppressed by lovastatin (10 µM) and nearly completely restored by mevalonate (100 µM). These results suggest that lovastatin has a direct cellular effect independent of a cholesterol-lowering effect and delays the onset and progression of diabetic nephropathy, at least in part, through suppression of glomerular expression of TGF-ß1.
This article has been cited by other articles:
 |
|
 |
|
  F. C. Cormack-Aboud, P. T. Brinkkoetter, J. W. Pippin, S. J. Shankland, and R. V. Durvasula Rosuvastatin protects against podocyte apoptosis in vitro Nephrol. Dial. Transplant., September 27, 2008; (2008) gfn528v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Peng, D. Wu, B. Gao, A. J. Ingram, B. Zhang, K. Chorneyko, R. McKenzie, and J. C. Krepinsky RhoA/Rho-Kinase Contribute to the Pathogenesis of Diabetic Renal Disease Diabetes, June 1, 2008; 57(6): 1683 - 1692. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-L. Koepke, M. Weber, E. Schulze-Lohoff, B. Beirowski, S. Segerer, and O. Gross Nephroprotective effect of the HMG-CoA-reductase inhibitor cerivastatin in a mouse model of progressive renal fibrosis in Alport syndrome Nephrol. Dial. Transplant., April 1, 2007; 22(4): 1062 - 1069. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Xu, L. Zeng, H. Peng, S. Chen, J. Jones, T.-L. Chew, M. M. Sadeghi, Y. S. Kanwar, and F. R. Danesh HMG-CoA reductase inhibitor simvastatin mitigates VEGF-induced "inside-out" signaling to extracellular matrix by preventing RhoA activation Am J Physiol Renal Physiol, November 1, 2006; 291(5): F995 - F1004. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. K. Banes-Berceli, S. Shaw, G. Ma, M. Brands, D. C. Eaton, D. M. Stern, D. Fulton, R. W. Caldwell, and M. B. Marrero Effect of simvastatin on high glucose- and angiotensin II-induced activation of the JAK/STAT pathway in mesangial cells Am J Physiol Renal Physiol, July 1, 2006; 291(1): F116 - F121. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. B. Marrero, A. K. Banes-Berceli, D. M. Stern, and D. C. Eaton Role of the JAK/STAT signaling pathway in diabetic nephropathy Am J Physiol Renal Physiol, April 1, 2006; 290(4): F762 - F768. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. D'Amico Statins and Renal Diseases: From Primary Prevention to Renal Replacement Therapy. J. Am. Soc. Nephrol., April 1, 2006; 17(4_suppl_2): S148 - S152. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. F. Schrijvers, A. S. De Vriese, and A. Flyvbjerg From Hyperglycemia to Diabetic Kidney Disease: The Role of Metabolic, Hemodynamic, Intracellular Factors and Growth Factors/Cytokines Endocr. Rev., December 1, 2004; 25(6): 971 - 1010. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Li, C. W. Yang, J. H. Park, S. W. Lim, B. K. Sun, J. Y. Jung, S. B. Kim, Y. S. Kim, J. Kim, and B. K. Bang Pravastatin treatment attenuates interstitial inflammation and fibrosis in a rat model of chronic cyclosporine-induced nephropathy Am J Physiol Renal Physiol, January 1, 2004; 286(1): F46 - F57. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Usui, K. Shikata, M. Matsuda, S. Okada, D. Ogawa, T. Yamashita, K. Hida, M. Satoh, J. Wada, and H. Makino HMG-CoA reductase inhibitor ameliorates diabetic nephropathy by its pleiotropic effects in rats Nephrol. Dial. Transplant., February 1, 2003; 18(2): 265 - 272. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Chaturvedi, C. G. Schalkwijk, H. Abrahamian, J. H. Fuller, and C. D.A. Stehouwer Circulating and Urinary Transforming Growth Factor {beta}1, Amadori Albumin, and Complications of Type 1 Diabetes: The EURODIAB Prospective Complications Study Diabetes Care, December 1, 2002; 25(12): 2320 - 2327. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Wang, S. Shaw, F. Amiri, D. C. Eaton, and M. B. Marrero Inhibition of the JAK/STAT Signaling Pathway Prevents the High Glucose-Induced Increase in TGF-{beta} and Fibronectin Synthesis in Mesangial Cells Diabetes, December 1, 2002; 51(12): 3505 - 3509. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Zoja, D. Corna, D. Camozzi, D. Cattaneo, D. Rottoli, C. Batani, C. Zanchi, M. Abbate, and G. Remuzzi How To Fully Protect the Kidney in a Severe Model of Progressive Nephropathy: A Multidrug Approach J. Am. Soc. Nephrol., December 1, 2002; 13(12): 2898 - 2908. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T.-M. Lee, S.-F. Su, and C.-H. Tsai Effect of Pravastatin on Proteinuria in Patients With Well-Controlled Hypertension Hypertension, July 1, 2002; 40(1): 67 - 73. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Porreca, C. Di Febbo, G. Baccante, M. Di Nisio, and F. Cuccurullo Increased transforming growth factor-beta1 circulating levels and production in human monocytes after 3-hydroxy-3-methyl-glutaryl-coenzyme a reductase inhibition with pravastatin J. Am. Coll. Cardiol., June 5, 2002; 39(11): 1752 - 1757. [Abstract] [Full Text] [PDF]
|
|
|
HOME
CURRENT ISSUE
ARCHIVES
JASN Express
ONLINE SUBMISSION
AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP |
Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673
